Josh Brown increases Pfizer holdings, citing CEO's optimistic view on cancer drug development as a potential global breakthrough. Despite Pfizer stock's 52-week low, its dividend offerings make it a viable option for passive income investors. PFE stock analysis reveals potential upside in the long run.